AIM ImmunoTech announces progress toward opening of breast cancer study at Roswell Park
AIM ImmunoTech announced progress toward the opening of Roswell Park Comprehensive Cancer Center's Phase 1 clinical study of chemokine modulation plus neoadjuvant chemotherapy in patients with early-stage triple negative breast cancer using Ampligen. September 10, 2019